Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology

30 November 2021

Villejuif and Castres, France, November 18th, 2021 – Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, and French pharmaceutical group Pierre Fabre today announce the signing of an exclusive license agreement on a series of Pierre Fabre patented small molecules targeting the Eukaryotic translation initiation factor 4A (eIF4A). This target is highly expressed in a variety of solid and hematologic cancers, including melanoma, and associated with resistance to many current therapies. Inhibiting eIF4A appears therefore to be a promising therapeutic approach.

In return for the license rights granted to Ribonexus, Pierre Fabre will receive development and sales milestones payments and royalties on future sales. Financial details are not disclosed.

To foster its pre-clinical development program, Ribonexus will benefit from Pierre Fabre’s knowledge and support on the pharmacology and chemistry of the licensed molecules.

Read more